Skip to main content

Table 1 Comparison of characteristics between lean and OW/OB patients with systemic juvenile idiopathic arthritis (SJIA)

From: Glucose metabolism in systemic juvenile idiopathic arthritis

Variables

Total (n = 39)

Lean (n = 28)

OW/OB (n = 11)

p-value

Age (years), mean (SD)

12.0 (4.6)

12.1 (5.2)

12 (3.1)

0.970

Gender, M (%)

21 (54)

14 (50)

7 (67)

0.442

Puberty, N (%)

   

0.693

 Prepuberty (Tanner I)

10 (26)

8 (29)

2 (18)

 

 Puberty (Tanner II-V)

29 (74)

20 (71)

9 (82)

 

BMI (kg/m2), mean (SD)

20.6 (5.9)

18.1 (3.4)

27.6 (5.4)

0.001

BMI SDS, median (IQR)

0.09 (-0.47 to 1.69)

-0.1 (-0.8 to -0.2)

2.3 (1.8–3.3)

0.001

Current prednisolone use, N (%)

Dose (mg/kg/day), median (IQR)

13 (33)

0.5 (0.17–1.02)

7 (25)

0.23 (0.11–0.67)

6 (55)

0.63 (0.22–1.05)

0.131

0.199

Cumulative prednisolone dose (mg/kg), median (IQR)

272

(113–661)

260

(90–616)

272

(124–1,057)

0.473

Cumulative methotrexate dose (mg/kg), median (IQR)

1,913

(28–5,406)

1,566

(46–5,660)

2,565

(0–5,172)

0.826

History of biologics use, N (%)

17 (43)

11 (39)

6 (55)

0.482

Disease duration

(months), median (IQR)

65 (45–117)

65 (46–110)

63 (25–132)

0.743

Systemic score,

median (IQR)

0.4 (0.2–0.6)

0.4 (0.2–0.5)

0.4 (0.3–0.6)

0.492

Cumulative JADAS-27,

median (IQR)

52 (33–83)

54 (31–85)

52 (45–71)

0.950

Disease status, N (%)

   

0.062

 Status 1: systemic features

1 (2)

0 (0)

1 (9)

 

 Status 2: arthritis only

7 (18)

7 (25)

0 (0)

 

 Status 3: inactive disease

31 (80)

21 (75)

10 (91)

 

Dyslipidemia, N (%)

22 (56)

14 (50)

8 (73)

0.288

TG (mg/dL), mean (SD)

96.8 (49.0)

88.8 (44.6)

116.9 (55.2)

0.107

TC (mg/dL), mean (SD)

177.9 (44.4)

174.4 (48.5)

187.0 (32.2)

0.431

HDL-C (mg/dL), mean (SD)

51.5 (12.1)

52.9 (12.4)

47.7 (11.2)

0.231

LDL-C (mg/dL), mean (SD)

116.4 (40.7)

112.7 (44.6)

125.9 (28.1)

0.368

Metabolic syndrome, N (%)

3 (7.7)

0 (0)

3 (27)

0.018

IGT, N (%)

1 (2.6)

0 (0)

1 (9)

0.282

FPG (mg/dL), mean (SD)

80.7 (6.4)

80.6 (5.3)

80.2 (8.7)

0.942

FPI (µIU/mL), median (IQR)

8.6 (4–13)

6 (3–10)

13 (11–15)

0.003

HOMA-IR, median (IQR)

1.8 (0.8–2.8)

1.2 (0.7–2.1)

2.6 (2.1–3.3)

0.003

WBISI, median (IQR)

5.0 (3.6–10.2)

5.8 (4.2–12.1)

3.7 (2.7–5.9)

0.042

IGI, median (IQR)

2.3 (1.3–3.4)

2.0  (0.9–3.4)

2.5 (2.0–3.5)

0.303

AUC-I / AUC-G, median (IQR)

0.6 (0.3–0.8)

0.3 (0.5–0.8)

0.7 (0.5–1.0)

0.254

DI, median (IQR)

13.6 (6.8–24.3)

14.1 (8.9–25.2)

8.6 (5.3–20.4)

0.454

  1. AUC-G area under the curve of glucose (mg⋅min/dL), AUC-I area under the curve of insulin (µIU⋅min/mL), AUC-I / AUC-G (µIU⋅dL/mg⋅mL), BMI body mass index, DI disposition index (dL2/mg⋅mL), FPG fasting plasma glucose, FPI fasting plasma insulin, HDL-C high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment for insulin resistance (µIU⋅mg/mg⋅dL), IGI insulinogenic index (µIU⋅dL/mg⋅mL), IGT impaired glucose tolerance, IQR interquartile range, JADAS Juvenile Arthritis Disease Activity Score, LDL-C low density lipoprotein cholesterol, M male, OW/OB overweight/obesity, SD standard deviation, TC total cholesterol, TG triglyceride, WBISI whole-body insulin sensitivity index (mL⋅dL/µIU⋅mg)
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096